AbbVie Inc. is 255.7x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($399.47 B vs $1.56 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SNDX | ABBV |
|---|---|---|
| Market cap | $1.56 B | $399.47 B |
| US-listed rank | #2297 | #28 |
| Revenue (latest FY) | $172.35M | $61.16B |
| Net income (latest FY) | -$285.40M | $4.23B |
| Net margin | -165.6% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 636 | 1,008 |
AbbVie Inc. is 255.7x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($399.47 B vs $1.56 B).
In their latest fiscal years, Syndax Pharmaceuticals Inc reported $172.35M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Syndax Pharmaceuticals Inc and AbbVie Inc., or browse the full rankings.